VK2735 Viking Therapeutics Weight Loss: Results, Side Effects, and FDA Timeline

VK2735 Viking Therapeutics Weight Loss: The 30-Second Status Check

What We Actually Verified on This Page

What Is VK2735? (The Plain-English Explainer)

VK2735 is an experimental weight loss drug from Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech in San Diego. It activates two gut hormone receptors at the same time — GLP-1 and GIP — which is the same dual mechanism used by Eli Lilly’s already-approved Zepbound. Viking is developing it as both a once-weekly injection and a once-daily pill, and it is currently in Phase 3 testing for the injection.

Who is making it?

Viking Therapeutics is a small publicly traded biotech led by CEO Brian Lian, Ph.D. They don’t have any FDA-approved products on the market yet — VK2735 is their lead candidate. If Phase 3 succeeds, Viking will either need to scale up its own commercial operation or partner with (or be acquired by) a larger pharma company to actually launch.

What does "GLP-1/GIP dual agonist" actually mean?

GLP-1 and GIP are two gut hormones that regulate appetite, blood sugar, and how your body handles food. A "dual agonist" activates both receptors at once. GLP-1 is the same hormone pathway hit by Wegovy and Ozempic — curbs appetite, slows stomach emptying, improves insulin signaling. GIP enhances the weight loss effect and, in some studies, reduces nausea.

The only other FDA-approved drug in this exact class is tirzepatide (Zepbound/Mounjaro). VK2735 is aiming to play in that same neighborhood.

Is VK2735 FDA Approved?

No. VK2735 is not FDA approved. As of April 2026, the weekly injection is in Phase 3 (both VANQUISH-1 and VANQUISH-2 are fully enrolled), the oral tablet has completed Phase 2 with Phase 3 expected Q3 2026, and a Phase 1 maintenance dosing study is fully enrolled with results expected Q3 2026. Our editorial projection: a realistic FDA decision window is late 2028 to 2029 if Phase 3 succeeds.

No shortcut exists. No "early access" program has been announced. No expanded access or compassionate use pathway has been publicly disclosed for VK2735 outside of clinical trial enrollment.

What has to happen before VK2735 could be approved

When Will VK2735 Be Available? (The Verified Timeline)

The earliest VK2735 could realistically be available is late 2028, with 2029 being the more likely window. Phase 3 trials are 78 weeks long, Viking has guided completion in 2027, an NDA would follow, and FDA review typically takes around 10 months.

How Much Will VK2735 Cost?

Unknown. Viking has not disclosed any pricing, and pricing won’t be set until closer to launch. For reference, Wegovy and Zepbound currently list at roughly $1,000–$1,400 per month at retail without coverage; with insurance or manufacturer programs, out-of-pocket can be much lower. If you want to compare what FDA-approved options actually cost today, our GLP-1 provider guides track current pricing across providers.

How Well Does VK2735 Work? (Phase 2 Data in Plain English)

In the Phase 2 VENTURE trial, the weekly injection produced up to 14.7% mean weight loss from baseline over 13 weeks, with up to 88% of patients at the highest dose hitting at least 10% weight loss compared to 4% on placebo. In the Phase 2 VENTURE-Oral trial, the daily pill produced up to 12.2% weight loss over 13 weeks. Both trials showed no plateau — weight loss was still trending down when the studies ended.

Those are big numbers for 13 weeks. But context matters: VK2735’s Phase 2 was a 13-week sprint, while Wegovy and Zepbound have data from 64–72-week marathons. Comparing them directly without acknowledging that gap is how people get misled.

VENTURE (weekly injection) — the headline numbers

• 176 adults, 13-week randomized placebo-controlled study
• Up to 14.7% mean weight loss from baseline
• Up to 13.1% placebo-adjusted weight loss
• Up to 88% of patients at the highest dose hit ≥10% weight loss (vs. 4% placebo)
• Discontinuation: 13% on VK2735 vs. 14% on placebo — balanced
• No plateau observed at 13 weeks
• Published in Obesity (January 2026)

VENTURE-Oral (daily tablet) — the headline numbers

• 280 adults, 13-week randomized placebo-controlled study
• Up to 12.2% mean weight loss from baseline (26.6 lbs at the highest dose)
• Up to 10.9% placebo-adjusted
• Up to 97% of participants hit ≥5% weight loss; up to 80% hit ≥10%
• Overall discontinuation across VK2735 groups: 28% vs. 18% placebo
• Exploratory maintenance arm: titrate to 90 mg, drop to 30 mg — weight loss held

13-week sprint vs. 72-week marathon: why direct comparisons don’t work yet

Different trial lengths, populations, endpoints, and baseline weights. The fair comparison comes after VANQUISH-1 reads out in 2027.

What Are the Side Effects of VK2735?

The most common side effects in Phase 2 were gastrointestinal — nausea, vomiting, constipation, and diarrhea — the same pattern seen across every GLP-1 class drug. In the injection trial, 43% had nausea (vs. 20% on placebo) and 18% had vomiting (vs. 0% on placebo). In the oral trial, 58% had nausea and 26% had vomiting. Viking reported the majority of these events as mild to moderate, and weekly rates dropped below 5% after the first few weeks.

Injection (VENTURE) side effect profile

Oral (VENTURE-Oral) side effect profile

Source: Viking IR, Aug 2025. Weekly nausea and vomiting rates dropped below 5% after week 3. Analysts expect Viking to carry the lower, better-tolerated doses forward into Phase 3.

Is VK2735 a Pill or a Shot?

Viking is developing both — a once-weekly subcutaneous injection and a once-daily oral tablet. They use the same active molecule. The injection is further along (Phase 3 fully enrolled). The pill’s Phase 3 is expected to start Q3 2026.

This is Viking’s unique pitch: most current GLP-1 programs require switching drugs if you want to change forms. Viking is arguing VK2735 could let a patient start on the injection to lose weight quickly, then transition to the oral tablet for long-term maintenance — staying on the exact same compound the whole time.

VK2735 vs. Wegovy, Zepbound, Foundayo, and the Full Pipeline

VK2735’s Phase 2 numbers put it in the conversation with tirzepatide (Zepbound) — which shares the same dual GLP-1/GIP mechanism. But Zepbound has 72 weeks of Phase 3 data across 2,500+ patients per its FDA label. VK2735 has 13 weeks of Phase 2 data across 176 patients. Anyone saying VK2735 is "as good as Zepbound" or "better than Wegovy" is comparing a sprint to a marathon.

Can You Buy VK2735 Right Now?

What we actually checked

Why "research chemical" VK2735 is dangerous

A vial labeled "VK2735, 5 mg" purchased from a research-chemical site may contain a different amount of active compound than the label claims, may not have been made under sterile conditions, may not even contain VK2735 at all, and offers no recourse if something goes wrong. No prescribing information, no pharmacy consultation, no liability insurance, no meaningful consumer protection. According to FDA, poor compounding practices can cause contamination, too much or too little active ingredient, and serious injury or death.

Red flags that a site is selling unapproved VK2735 illegally

• “Research use only” disclaimer but marketing targeted at weight loss consumers
• “No prescription needed”
• Claims of being “the same as” an approved medication
• Before-and-after photos
• Crypto-only or anonymous payment
• No company name, business address, or pharmacy license displayed
• No licensed prescriber involved

The only legal way to access VK2735 today

Clinical trial participation. As of April 2026, VANQUISH-1, VANQUISH-2, and the Phase 1 maintenance study are all fully enrolled. The oral Phase 3 program expected to start Q3 2026 will be the next realistic enrollment opportunity. Check ClinicalTrials.gov directly for the latest status.

NCT IDs to track: NCT07104500 (VANQUISH-1), NCT07104383 (VANQUISH-2).

VK2735 Clinical Trial Status (Current as of April 24, 2026)

Should You Wait for VK2735 or Start Something Available Now?

It depends on your situation. Waiting three-plus years for a drug that may or may not be approved is a reasonable choice for some people. Starting an FDA-approved option this month — while VK2735 finishes Phase 3 — is the right choice for most.

What to Do If You Don’t Want to Wait Until 2028+

If you’ve decided that waiting three-plus years isn’t your path, the two telehealth providers most relevant to the clinical territory VK2735 is trying to enter are Ro and Eden. Neither sells VK2735 — nothing does — but both prescribe currently-approved medications that occupy the same space.

Not sure which fits? The 60-second quiz covers the full market →

The Expert Perspective

Two public statements worth knowing, both from the oral Phase 2 readout in August 2025:

What’s Changing Next (Put These on Your Calendar)

• Q3 2026 Maintenance dosing study readout — will tell us whether weekly oral or monthly injection maintenance is viable
• Q3 2026 Oral VK2735 Phase 3 program initiation — will reopen enrollment windows
• 2027 VANQUISH-1 and VANQUISH-2 study completion — the real efficacy picture arrives here
• Late 2027/2028 Expected NDA submission if Phase 3 succeeds
• 2028–2029 FDA decision on subcutaneous VK2735 (editorial projection)

We’ll update this page within 7 days of any major Viking press release, FDA action, or trial readout. Last verified: April 24, 2026. Next scheduled verification: July 24, 2026.

VK2735 Frequently Asked Questions